Targets › GLB1
2 programs from 2 companies in 2 trials: 2 Phase 1; Metabolic and endocrine; next expected readout Feb 2028.
[Isoform 1]: Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans..; FUNCTION: [Isoform 2]: Has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the…. (UniProt, P16278)
Open in Phaseline: the race on GLB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gemma Biotherapeutics | PBGM01 AAVhu68 viral vector delivering functional GLB1 gene | GLB1 | Phase 1 | GM1 Gangliosidosis | Feb 2028 |
| National Human Genome Research Institute (NHGRI) | AAV9-GLB1 AAV9 vector expressing human beta-galactosidase (GLB1 gene product) | GLB1 | Phase 1 | Lysosomal Diseases | Jan 2030 |
GM1 Gangliosidosis (1) Lysosomal Diseases (1)
protein or peptide (1), mixed (1)
Gemma Biotherapeutics (1) National Human Genome Research Institute (NHGRI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.